use of neoadjuvant approaches in breast cancer during the covid-19 pandemic
Published 2 years ago • 19 plays • Length 2:35Download video MP4
Download video MP3
Similar videos
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
2:04
sabcs 2020: contextualising the impact of the covid-19 pandemic on breast cancer care
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
2:45
the impact of the covid-19 pandemic on the management of patients with breast cancer
-
17:31
prioritising patients for breast cancer surgery during covid-19: a surgeon's perspective
-
1:59
effectiveness of icis in the neoadjuvant and post-neoadjuvant breast cancer setting
-
3:33
assessing the global impact of the covid-19 pandemic on patients receiving breast cancer care
-
2:20
management of patients with breast cancer during covid-19
-
7:37
prioritising patients for breast cancer surgery during covid-19: new treatment algorithm
-
3:11
st. gallen consensus 2021: neoadjuvant and adjuvant therapy for her2 breast cancer
-
2:31
adjuvant/neoadjuvant therapy trials for breast cancer at sabcs 2021
-
8:30
cdk4/6 inhibitors in er metastatic breast cancer during the covid-19 pandemic
-
1:29
the predictive value of treatment response after neoadjuvant therapy
-
3:01
alternate: neoadjuvant chemotherapy in er her2- breast cancer
-
14:30
considerations in treatment of breast cancer during covid 19 pandemic | medvarsity
-
2:51
personalized ctdna during neoadjuvant therapy in pts with early-stage breast cancer
-
2:44
adapting and managing breast cancer treatment in the face of covid-19
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
0:53
what is neoadjuvant therapy?